Boehringer adds $250M to value of Variant pact by expanding into cardiovascular disease
Fuente:
FierceBiotech
Boehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover cardiovascular disease to the tune of $250 million.